Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
  1. Home
  3. The Effect Of Metabolic Syndrome On Prognosis Of Diffuse Large B-cell Lymphoma.
  1. Home
  3. The Effect Of Metabolic Syndrome On Prognosis Of Diffuse Large B-cell Lymphoma.

Related Experiment Video

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.0K

The effect of metabolic syndrome on prognosis of diffuse large B-cell lymphoma.

Wenjing Xiong1, Liru Li1, Xue Hui1

  • 1Department of Clinical Oncology, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, 150040, China.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|March 30, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Metabolic syndrome (MetS) is linked to poorer outcomes in diffuse large B-cell lymphoma (DLBCL) patients. Pre-treatment MetS, along with IPI score and rituximab usage, independently predicts a worse prognosis.

Keywords:
Diffuse large B-cell lymphomaMetabolic syndromeOverall survivalProgression-free survival

More Related Videos

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.5K
Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.5K

Related Experiment Videos

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.0K
Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
09:08

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling

Published on: October 14, 2021

5.5K
Assessment of the Metabolic Profile of Primary Leukemia Cells
06:21

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

10.5K

Area of Science:

  • Oncology
  • Hematology
  • Metabolic Diseases

Background:

  • Metabolic syndrome (MetS) is associated with cancer prognosis but its role in diffuse large B-cell lymphoma (DLBCL) is unclear.
  • Understanding factors influencing DLBCL prognosis is crucial for patient outcomes.

Purpose of the Study:

  • To investigate the impact of MetS and clinicopathological variables on DLBCL prognosis.
  • To identify independent prognostic factors in DLBCL patients.

Main Methods:

  • Retrospective analysis of clinical and pathological data from 319 DLBCL patients (2012-2020).
  • Statistical analysis using SPSS, including t-tests and univariate/multivariate COX regression.

Main Results:

  • MetS presence correlated with poorer overall survival (OS) and progression-free survival (PFS).
  • Independent risk factors for DLBCL prognosis included MetS, IPI score, Ki-67 expression, and rituximab usage.
  • Age, tumor staging, and lactate dehydrogenase levels were also linked to survival.

    • Conclusions:

    • Pre-treatment MetS is associated with significantly shorter OS and PFS in DLBCL patients.
    • MetS is an independent negative prognostic factor in DLBCL, alongside IPI score, Ki-67, and rituximab.
    • These findings highlight MetS as a critical factor in DLBCL management.